PD-L1 expression in ovarian clear cell carcinoma using the 22C3 pharmDx assay

• Egile Nagusiak: Yike Gao (Egilea), Boju Pan (Egilea), Hongbao Jia (Egilea), Yang Zhang (Egilea), Shu Wang (Egilea), Yuming Wang (Egilea), Sumei Zhang (Egilea), Mei Li (Egilea), Anqi Wang (Egilea), Xiaoxi Wang (Egilea), Kun Zhao (Egilea), Zixin Zhang (Egilea), Jian Sun (Egilea), Dan Guo (Egilea), Zhiyong Liang (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2024-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Ovarian clear cell carcinoma (OCCC), well known for its chemoresistance to platinum-based chemotherapy, exhibited a good response in clinical trials of anti-PD-1/PD-L1 inhibitors. By assessing PD-L1 expression, we sought to determine the potential therapeutic benefit of PD-1/PD-L...